ESErin C. Stone

Erin C. Stone

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Erin C. Stone has a total of 40 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Germicidal ultraviolet to reduce transmission of respiratory infections indoors: a systematic review

    by Grant P. Higerd-Rusli, Erin C. Stone, Seth A. Hoffman, Ernest R. Blatchley, David T. Kuhar, Stephen P. Luby, Stephen B. Martin, Richard A. Martinello, C. Cameron Miller, Katherine Ratliff, et al.

    Background: Respiratory infections that transmit through air contribute substantially to global morbidity and mortality. Although preclinical data on germicidal ultraviolet (GUV) for air treatment are promising, its real-world effectiveness remains incompletely understood. Purpose: Review effectiveness and safety of GUV for preventing respiratory infection transmission. Data sources: Medline, Embase, Global Health, Cochrane Library, CINAHL, Engineering Village, Epistemonikos, Scopus, and Environmental Science Collection from inception through December 2025. Study selection: Studies of GUV with a comparator, measuring human outcomes including respiratory infections, absenteeism, or adverse events. Data extraction: At least two investigators extracted data. Data synthesis: We identified 57 reports describing 40 studies published between 1940 and 2025: 30 non-randomized controlled trials, 4 randomized controlled trials (RCTs), 4 case series, 1 cohort study, and 1 cross-sectional study. Non-randomized studies indicated GUV reduces infections with high transmissibility through air (measles and chickenpox), although results were mixed for undifferentiated respiratory illnesses and absenteeism. Two RCTs were inconclusive or showed only modest effects. Safety monitoring in 16 studies identified no increased eye or skin irritation from properly installed GUV. All studies had at least one threat to validity; 89% were non-randomized, and 83% lacked statistical power calculations. Limitations: Heterogeneous study designs, interventions, and outcomes precluded meta-analysis. Conclusions: Several older clinical studies indicated that GUV reduces infections with high transmissibility through air, but its broader effectiveness against respiratory infection remains uncertain. Inconclusive results may reflect methodological and epidemiological limitations rather than true ineffectiveness. Adequately powered RCTs with robust clinical endpoints are needed. Registration: https://osf.io/fg6qx

  • Open Access

    2025 US Public Health Service Guidelines for the Management of Occupational Exposures to Human Immunodeficiency Virus and Recommendations for Post-exposure Prophylaxis in Healthcare Settings

    by Aaron D. Kofman, Kimberly A. Struble, Walid Heneine, Britt Gayle, Marie A. de Perio, Devon L. Okasako-Schmucker, Christine N. So, Laura E. Anderson, Erin C. Stone, David K. Henderson, et al.

    These guidelines update the 2013 “Updated US Public Health Service (PHS) Guidelines for the Management of Occupational Exposures to Human Immunodeficiency Virus and Recommendations for Postexposure Prophylaxis,” hereafter referred to as the 2013 PHS Guidelines. 1,2 The availability of new medication options, new information on the window of detection for different human immunodeficiency virus (HIV) tests, and the risk of transmission from people with undetectable viral loads prompted this update. The primary intended audience for these recommendations remains anyone involved in the provision of HIV post-exposure management to healthcare personnel (HCP). The U.S. Centers for Disease Control and Prevention assembled a working group of representatives from federal agencies in the U.S. Department of Health and Human Services (HHS) who identified the priority topics for update and conducted systematic literature reviews to formulate recommendations (see Appendix). All recommendations were reviewed by the Healthcare Infection Control Practices Advisory Committee (HICPAC) at public meetings, and by a non-consensus forming panel of external experts. New evidence-based recommendations are developed using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) framework and classified according to the HICPAC recommendation scheme when evidence supported recommendation development. 3,4 Other recommendations in this document are classified as good practice statements according to the criteria set forth by GRADE. 5 The working group solicited additional feedback on recommendations from relevant agencies, subject-matter experts, and the public. Recommendations that have changed since the 2013 PHS guidelines include: new antiretroviral drug regimens for post-exposure prophylaxis (PEP); a shortened duration of post-exposure follow-up HIV testing; elimination of routine laboratory tests for antiretroviral drug toxicity; and considerations for PEP for HCP with exposures to source patients with undetectable viral loads. Important strategies in the principles of exposure management remain: primary prevention strategies; the prompt reporting and management of occupational exposures; adherence to recommended HIV PEP regimens when indicated; the role of expert consultation in management of exposures; and follow-up of exposed HCP.


  • Engineering Infection Controls to Reduce Indoor Transmission of Respiratory Infections

    by Amiran Baduashvili, Lewis Radonovich, Louis Leslie, Stephanie Pease, Claire Brickson, Leela Chockalingam, Natalie Banacos, Beret Fitzgerald, Jeffrey Wagner, William P. Bahnfleth, et al.

    Engineering infection controls include a wide range of interventions used indoors to reduce occupants' exposure to respiratory pathogens. To identify and describe primary studies evaluating the effects of engineering infection control interventions designed to reduce the spread of respiratory infections transmitted through indoor air. MEDLINE, Embase, Global Health, Cochrane Central Register of Controlled Trials, CINAHL, Scopus, and Environmental Science Collection from database inception to 12 December 2023. English-language primary research articles evaluating engineering infection control interventions. Publication information, population characteristics, intervention details, and all relevant outcomes were abstracted by a reviewer and verified by a second, senior reviewer. A total of 672 studies published between 1929 and 2024 were identified. Most (n = 606) evaluated environmental samples only, 57 included human participants, and 9 included sentinel animal subjects. About half of the studies included at least 1 intervention classified as pathogen inactivation (n = 405), with fewer involving pathogen removal (n = 200) or air exchange or dilution (n = 143). Across all studies, about half (n = 332) measured the quantity of viable nonpathogenic organisms from air samples, followed by the quantity of nonbiological particulates (n = 197) or viable pathogenic organisms (n = 149). Harms, such as toxic byproducts, were rarely measured. Exclusion of non-English-language publications and gray literature. There is substantial heterogeneity in the available evidence. Gaps in evidence include studies measuring efficacy outcomes that are highly relevant for human infection transmission or harms. Refinements in classification of interventions and outcomes could strengthen reporting of these evaluations. National Institute for Occupational Safety and Health at the Centers for Disease Control and Prevention. (Registered on Open Science Framework [https://osf.io/5zmhd]).


  • Open Access

    Risk period for transmission of SARS-CoV-2 and seasonal influenza: a rapid review

    by Erin C. Stone, Devon L. Okasako-Schmucker, Joanna Taliano, Melissa Schaefer, David T. Kuhar

    Background: Restricting infectious healthcare workers (HCWs) from the workplace is an important infection prevention strategy. The duration of viral shedding or symptoms are often used as proxies for the infectious period in adults but may not accurately estimate it.Objective: To determine the risk period for transmission among previously healthy adults infected with SARS-CoV-2 omicron variant (omicron) or influenza A (influenza) by examining the duration of shedding and symptoms, and day of symptom onset in secondary cases of transmission pairs.Design: Rapid reviewMethods: This rapid review adhered to PRISMA-ScR; five databases were searched. The cumulative daily proportion of participants with an outcome of interest was calculated for each study and summarized.Results: Forty-three studies were included. Shedding resolved among ≥ 70% of participants by the end of day nine post symptom onset for omicron, and day seven for influenza; and for ≥ 90% of participants, by the end of day 10 for omicron and day nine for influenza. Two studies suggested shedding continues > 24 hours post-fever resolution for both viruses. Symptom onset occurred in ≥ 80% of secondary cases by the end of day seven post-primary case symptom onset for omicron and day six for influenza.Conclusions: Omicron shedding is consistent with previous recommendations to exclude infected HCWs from work for 10 days; and influenza follows a similar trend. Earlier symptom onset in most secondary cases for both pathogens indicates that, despite persistent viral shedding, most transmission occurs earlier; and the cumulative serial interval might better approximate the duration of infectiousness.